Ernexa Therapeutics Inc. (NASDAQ:ERNA) Sees Significant Drop in Short Interest

Ernexa Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a significant decline in short interest in May. As of May 29th, there was short interest totaling 44,811 shares, a decline of 72.4% from the May 14th total of 162,618 shares. Based on an average daily volume of 99,259 shares, the short-interest ratio is presently 0.5 days. Currently, 3.9% of the shares of the stock are sold short.

Ernexa Therapeutics Trading Up 3.3%

Shares of NASDAQ ERNA traded up $0.21 during mid-day trading on Thursday, reaching $6.55. The company had a trading volume of 22,634 shares, compared to its average volume of 951,818. The stock has a market cap of $7.66 million, a PE ratio of -0.25 and a beta of 2.49. The company has a 50-day moving average price of $7.43 and a two-hundred day moving average price of $16.50. Ernexa Therapeutics has a 1-year low of $3.18 and a 1-year high of $71.50.

Ernexa Therapeutics (NASDAQ:ERNA) last issued its earnings results on Monday, May 11th. The company reported ($6.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00). On average, research analysts expect that Ernexa Therapeutics will post -18.02 EPS for the current year.

Hedge Funds Weigh In On Ernexa Therapeutics

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new position in Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics as of its most recent SEC filing. 70.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ERNA shares. Wall Street Zen cut Ernexa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Tuesday, April 21st. Zacks Research raised Ernexa Therapeutics to a “hold” rating in a research note on Monday, May 11th. Finally, Brookline Capital Markets assumed coverage on Ernexa Therapeutics in a research note on Thursday, May 7th. They issued a “buy” rating and a $30.00 price objective on the stock. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $30.00.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.